NEW YORK, NY / ACCESSWIRE / August 21, 2017 / Geopolitical concerns combined with the resignation of multiple advisors to President Trump pressured markets lower last week. On Friday, the Dow Jones Industrial Average declined 0.35 percent to close at 21,674.51, down 0.84 percent for the week, while the S&P 500 Index fell 0.18 percent to close at 2,425.55, down 0.64 percent for the week. The Nasdaq Composite Index decreased 0.09 percent to close at 6,216.53, down 0.65 percent for the week.
"Longer-term trends at this point remain intact, so this remains a short-term pullback only. And it's tough to make too much of this," said Mark Newton, managing member at Newton Advisors, in a note, according to CNBC.
RDI Initiates Coverage on:
Amicus Therapeutics Inc.
Ritter Pharmaceuticals Inc.
Amicus Therapeutics Inc.'s stock moved 1.79% higher Friday, to close the day at $12.51. The stock recorded a trading volume of 3,424,906 shares, which was below its three months average volume of 3,772,220 shares. In the last year Amicus Therapeutics Inc.'s shares have traded in a range of 4.41 - 14.05. The share price has gained 183.67% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $12.55 is greater than its 200-day moving average of $8.75. Shares of Amicus Therapeutics have gained approximately 151.71 percent year-to-date.
Access RDI's Amicus Therapeutics Inc. Research Report at:
On Friday, shares OF Ritter Pharmaceuticals Inc. recorded a trading volume of 819,702 shares, which was above the three months average volume of 383,227 shares. The stock ended the day 13.21% higher at 0.60. The share price has gained 20.00% from its 52 week low with a 52 week trading range of 0.50 - 3.75.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.57 is below its 200-day moving average of $1.33. Shares of Ritter Pharmaceuticals have fallen approximately 77.86 percent year-to-date.
Access RDI’s Ritter Pharmaceuticals Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.